First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC

Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC. The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies. In earlier Phase I PROCEADE-CRC-01, Precem-TcT showed predictable and manageable safety in over 100 pretreated mCRC patients. Credit: Jo Panuwat D / Shutterstock.com. Merck KGaA (Merck) has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti‑carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody-drug conjugate (ADC) precemtabart tocentecan (Precem TcT) for metastatic colorectal cancer (mCRC). The trial…

Source: Clinical Trials Arena